Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Krithika N Kodumudi"'
Autor:
Krithika N Kodumudi, Jessica Siegel, Amy M Weber, Ellen Scott, Amod A Sarnaik, Shari Pilon-Thomas
Publikováno v:
PLoS ONE, Vol 11, Iss 4, p e0153053 (2016)
Tumor-infiltrating lymphocytes (TIL) has been associated with improved survival in cancer patients. Within the tumor microenvironment, regulatory cells and expression of co-inhibitory immune checkpoint molecules can lead to the inactivation of TIL. H
Externí odkaz:
https://doaj.org/article/7413bc1f36914de8bb309c52db9080aa
Publikováno v:
Journal of International Clinical Dental Research Organization, Vol 2, Iss 1, Pp 24-29 (2010)
Background: Periodontitis is a common bacterial infection precipitated by exaggerated host responses to the oral microorganisms, As the first cells to encounter the oral pathogens the gingival epithelial cells (GEC) respond via toll-like receptors (T
Externí odkaz:
https://doaj.org/article/ea52300cab9b422da31475c59c94f6f5
Autor:
Nadia Nocera Zachariah, Amrita Basu, Namrata Gautam, Ganesan Ramamoorthi, Krithika N. Kodumudi, Nagi B. Kumar, Loretta Loftus, Brian J. Czerniecki
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Breast cancer (BC) prevention remains the ultimate cost-effective method to reduce the global burden of invasive breast cancer (IBC). To date, surgery and chemoprevention remain the main risk-reducing modalities for those with hereditary cancer syndr
Externí odkaz:
https://doaj.org/article/ec880474820f49c39ed7097d18ed36b6
Autor:
Robert J. Gillies, Arig Ibrahim-Hashim, James J. Mulé, Jonathan W. Wojtkowiak, Mehdi Damaghi, Kimberly Luddy, Amy M. Weber, Shonagh Russell, Asmaa E. El-Kenawi, Krithika N. Kodumudi, Shari Pilon-Thomas
Cancer immunotherapies, such as immune checkpoint blockade or adoptive T-cell transfer, can lead to durable responses in the clinic, but response rates remain low due to undefined suppression mechanisms. Solid tumors are characterized by a highly aci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5688543a11a663550d998bca4f5c7110
https://doi.org/10.1158/0008-5472.c.6507795
https://doi.org/10.1158/0008-5472.c.6507795
Autor:
Robert J. Gillies, Arig Ibrahim-Hashim, James J. Mulé, Jonathan W. Wojtkowiak, Mehdi Damaghi, Kimberly Luddy, Amy M. Weber, Shonagh Russell, Asmaa E. El-Kenawi, Krithika N. Kodumudi, Shari Pilon-Thomas
Supplemental Figure S1: Inhibition of PI3 kinase signaling leads to loss of T cell function. Activated T cells were cultured at pH 6.6 or 7.4 for 24h in presence or absence of the PI3K Supplemental Figure S2: OT-1 T cell metabolism. OT-1 T cells were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a909f5b747f5783e8dac9d8fb9b21d0
https://doi.org/10.1158/0008-5472.22409493.v1
https://doi.org/10.1158/0008-5472.22409493.v1
Autor:
Robert J. Gillies, Arig Ibrahim-Hashim, James J. Mulé, Jonathan W. Wojtkowiak, Mehdi Damaghi, Kimberly Luddy, Amy M. Weber, Shonagh Russell, Asmaa E. El-Kenawi, Krithika N. Kodumudi, Shari Pilon-Thomas
Supplemental Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd086b4139c2191bacbf9e41100b9cc5
https://doi.org/10.1158/0008-5472.22409496.v1
https://doi.org/10.1158/0008-5472.22409496.v1
Autor:
Amrita, Basu, Gabriella K, Albert, Sabrina, Awshah, Jashodeep, Datta, Krithika N, Kodumudi, Corey, Gallen, Amber, Beyer, Keiran S M, Smalley, Paulo C, Rodriguez, Derek R, Duckett, Peter A, Forsyth, Aixa, Soyano, Gary K, Koski, Ricardo, Lima Barros Costa, Heather, Han, Hatem, Soliman, Marie Catherine, Lee, Pawel, Kalinski, Brian J, Czerniecki
Publikováno v:
Cancer immunology research. 10(1)
The HER3/ERBB3 receptor is an oncogenic receptor tyrosine kinase that forms heterodimers with EGFR family members and is overexpressed in numerous cancers. HER3 overexpression associates with reduced survival and acquired resistance to targeted thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0607fc7a71a38ee7f7f7b21c39d200dc
https://pubmed.ncbi.nlm.nih.gov/34785506
https://pubmed.ncbi.nlm.nih.gov/34785506
Autor:
Brittany Bunch, Krithika N. Kodumudi, Jared Ehrhart, Matt Weitzman, Olivia MacIntosh, Kelly Sussman, Soner Altiok
Publikováno v:
Cancer Research. 82:246-246
Background: The receptor tyrosine kinase inhibitor (TKI) Sunitinib has proven useful in the treatment of a variety of tumors. Sunitinib has shown therapeutic activity in patients with metastatic renal cell carcinoma and currently represents a frontli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d76c34ee6c199f68937e9cdb07b2cc0
https://doi.org/10.1158/1538-7445.am2022-246
https://doi.org/10.1158/1538-7445.am2022-246
Autor:
Krithika N. Kodumudi, Ganesan Ramamoorthi, Colin Snyder, Amrita Basu, Yongsheng Jia, Sabrina Awshah, Amber P. Beyer, Doris Wiener, Lian Lam, Hongtao Zhang, Mark I. Greene, Ricardo L. B. Costa, Brian J. Czerniecki
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 10 (2019)
Frontiers in Immunology, Vol 10 (2019)
Patients with metastatic HER2 breast cancer (MBC) often become resistant to HER 2 targeted therapy and have recurrence of disease. The Panacea trial suggested that HER2 MBC patients were more likely to respond to checkpoint therapy if TIL were presen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::053d4837a89776b9bcca8e061dbfeac7
http://europepmc.org/articles/PMC6702967
http://europepmc.org/articles/PMC6702967